




RealRate

PHARMACEUTICAL 2019

CHINOOK THERAPEUTICS INC. Rank 220 of 363





RealRate

PHARMACEUTICAL 2019

CHINOOK THERAPEUTICS INC. Rank 220 of 363



The relative strengths and weaknesses of CHINOOK THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CHINOOK THERAPEUTICS INC. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 33% points. The greatest weakness of CHINOOK THERAPEUTICS INC. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 136% points.

The company's Economic Capital Ratio, given in the ranking table, is 47%, being 10% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	282,976
Cost of Goods Sold	0
Intangible Assets	33,469
Liabilities, Current	30,517
Liabilities, Non-Current	173,511
Other Assets	11,902
Other Compr. Net Income	-953
Other Expenses	3,793
Other Liabilities	18,165
Other Net Income	5,220
Other Revenues	15,087
Property and Equipment	29,157
Research and Development	75,836
Selling, General and Administrative Expense	36,035

Output Variable	Value in 1000 USD
Assets	357,504
Liabilities	222,193
Expenses	115,664
Revenues	15,087
Stockholders Equity	135,311
Net Income	-95,357
Comprehensive Net Income	-95,834
Economic Capital Ratio	47%